By Helgi Library - April 2, 2020
GlaxoSmithKline Czech Republic's total assets reached CZK 1,520 mil at the end of 2017, down 0.266% compared to the previous yea...
| Profit Statement | 2015 | 2016 | 2017 | |
| Sales | CZK mil | 4,378 | 3,393 | 2,897 |
| Gross Profit | CZK mil | 497 | 384 | 335 |
| EBITDA | CZK mil | 139 | 62.4 | 97.4 |
| EBIT | CZK mil | 127 | 54.1 | 89.9 |
| Financing Cost | CZK mil | 1.37 | 0.602 | 0.858 |
| Pre-Tax Profit | CZK mil | 156 | 53.5 | 89.0 |
| Net Profit | CZK mil | 125 | 38.0 | 65.4 |
| Dividends | CZK mil | 125 | 38.0 | ... |
| Balance Sheet | 2015 | 2016 | 2017 | |
| Total Assets | CZK mil | 2,107 | 1,524 | 1,520 |
| Non-Current Assets | CZK mil | 18.8 | 16.2 | 10.1 |
| Current Assets | CZK mil | 2,066 | 1,493 | 1,496 |
| Working Capital | CZK mil | 983 | 1,049 | 1,154 |
| Shareholders' Equity | CZK mil | 1,338 | 1,524 | 1,520 |
| Liabilities | CZK mil | 768 | 0 | 0 |
| Total Debt | CZK mil | 0 | 0 | 0 |
| Net Debt | CZK mil | -515 | -350 | -209 |
| Ratios | 2015 | 2016 | 2017 | |
| ROE | % | 9.44 | 2.66 | 4.30 |
| ROCE | % | 11.2 | 3.68 | 5.87 |
| Gross Margin | % | 11.4 | 11.3 | 11.6 |
| EBITDA Margin | % | 3.17 | 1.84 | 3.36 |
| EBIT Margin | % | 2.91 | 1.59 | 3.10 |
| Net Margin | % | 2.85 | 1.12 | 2.26 |
| Net Debt/EBITDA | -3.71 | -5.61 | -2.15 | |
| Net Debt/Equity | % | -38.5 | -23.0 | -13.8 |
| Cost of Financing | % | ... | ... | ... |
| Cash Flow | 2015 | 2016 | 2017 | |
| Total Cash From Operations | CZK mil | ... | -142 | -78.2 |
| Total Cash From Investing | CZK mil | ... | -7.05 | -1.83 |
| Total Cash From Financing | CZK mil | ... | -125 | -38.0 |
| Net Change In Cash | CZK mil | ... | -274 | -118 |
| Cash Conversion Cycle | days | 85.4 | 119 | 155 |
| Cash Earnings | CZK mil | 136 | 46.4 | 72.9 |
| Free Cash Flow | CZK mil | ... | -150 | -80.1 |
Get all company financials in excel:
| summary | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | ||||||||||||||||
| Sales | CZK mil | 5,828 | 5,735 | 5,653 | 4,855 | 4,378 | ||||||||||
| Gross Profit | CZK mil | 622 | 710 | 653 | 596 | 497 | ||||||||||
| EBIT | CZK mil | 291 | 216 | 169 | 119 | 127 | ||||||||||
| Net Profit | CZK mil | 240 | 164 | 127 | 87.7 | 125 | ||||||||||
| ROE | % | 19.3 | 12.0 | 9.41 | 6.64 | 9.44 | ||||||||||
| EBIT Margin | % | 5.00 | 3.76 | 2.98 | 2.46 | 2.91 | ||||||||||
| Net Margin | % | 4.12 | 2.86 | 2.25 | 1.81 | 2.85 | ||||||||||
| Employees | 264 | 262 | 239 | 246 | 183 | |||||||||||
| balance sheet | ||||||||||||||||
| Total Assets | CZK mil | 3,166 | 2,418 | 2,374 | 2,019 | 2,107 | ||||||||||
| Non-Current Assets | CZK mil | 41.0 | 57.7 | 47.5 | 33.7 | 18.8 | ||||||||||
| Current Assets | CZK mil | 3,084 | 2,321 | 2,295 | 1,959 | 2,066 | ||||||||||
| Shareholders' Equity | CZK mil | 1,363 | 1,369 | 1,340 | 1,301 | 1,338 | ||||||||||
| Liabilities | CZK mil | 1,802 | 1,050 | 1,034 | 718 | 768 | ||||||||||
| Non-Current Liabilities | CZK mil | 55.0 | 59.5 | 91.3 | 61.5 | 55.7 | ||||||||||
| Current Liabilities | CZK mil | 1,747 | 990 | 943 | 656 | 713 | ||||||||||
| Net Debt/EBITDA | 0.438 | 1.02 | 1.69 | -0.001 | -3.71 | |||||||||||
| Net Debt/Equity | % | 9.97 | 17.5 | 23.8 | -0.015 | -38.5 | ||||||||||
| Cost of Financing | % | ... | 1.64 | 1.09 | 1.94 | 1.42 | ... | ... | ... | |||||||
| cash flow | ||||||||||||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... |
| income statement | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | ||||||||||||||||
| Sales | CZK mil | 5,828 | 5,735 | 5,653 | 4,855 | 4,378 | ||||||||||
| Cost of Goods & Services | CZK mil | 5,207 | 5,026 | 5,000 | 4,259 | 3,880 | ||||||||||
| Gross Profit | CZK mil | 622 | 710 | 653 | 596 | 497 | ||||||||||
| Staff Cost | CZK mil | 284 | 315 | 335 | 349 | 298 | ||||||||||
| Other Cost | CZK mil | 27.6 | 161 | 129 | 107 | 61.1 | ||||||||||
| EBITDA | CZK mil | 310 | 234 | 189 | 139 | 139 | ||||||||||
| Depreciation | CZK mil | 19.3 | 18.3 | 19.9 | 20.2 | 11.6 | ||||||||||
| EBIT | CZK mil | 291 | 216 | 169 | 119 | 127 | ||||||||||
| Financing Cost | CZK mil | 4.67 | 3.27 | 5.44 | 2.27 | 1.37 | ||||||||||
| Extraordinary Cost | CZK mil | 0 | 0 | 0 | 0 | -30.0 | ||||||||||
| Pre-Tax Profit | CZK mil | 286 | 212 | 163 | 117 | 156 | ||||||||||
| Tax | CZK mil | 46.4 | 48.6 | 35.8 | 29.3 | 25.6 | ||||||||||
| Minorities | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Net Profit | CZK mil | 240 | 164 | 127 | 87.7 | 125 | ||||||||||
| Dividends | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | 125 | ... | |
| growth rates | ||||||||||||||||
| Total Revenue Growth | % | ... | -5.48 | -1.59 | -1.43 | -14.1 | -9.83 | |||||||||
| Operating Cost Growth | % | ... | -34.4 | 52.8 | -2.39 | -1.60 | -21.5 | |||||||||
| EBITDA Growth | % | ... | 27.4 | -24.7 | -19.4 | -26.0 | -0.486 | |||||||||
| EBIT Growth | % | ... | 31.9 | -25.9 | -21.8 | -29.3 | 6.70 | |||||||||
| Pre-Tax Profit Growth | % | ... | 32.4 | -25.9 | -23.1 | -28.4 | 33.3 | |||||||||
| Net Profit Growth | % | ... | 45.3 | -31.8 | -22.2 | -31.2 | 42.1 | |||||||||
| ratios | ||||||||||||||||
| ROE | % | 19.3 | 12.0 | 9.41 | 6.64 | 9.44 | ||||||||||
| ROCE | % | ... | 14.3 | 9.26 | 6.91 | 5.65 | 11.2 | |||||||||
| Gross Margin | % | 10.7 | 12.4 | 11.5 | 12.3 | 11.4 | ||||||||||
| EBITDA Margin | % | 5.33 | 4.08 | 3.34 | 2.87 | 3.17 | ||||||||||
| EBIT Margin | % | 5.00 | 3.76 | 2.98 | 2.46 | 2.91 | ||||||||||
| Net Margin | % | 4.12 | 2.86 | 2.25 | 1.81 | 2.85 | ||||||||||
| Payout Ratio | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | 100 | ... | |
| Cost of Financing | % | ... | 1.64 | 1.09 | 1.94 | 1.42 | ... | ... | ... | |||||||
| Net Debt/EBITDA | 0.438 | 1.02 | 1.69 | -0.001 | -3.71 |
| balance sheet | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| balance sheet | ||||||||||||||||
| Non-Current Assets | CZK mil | 41.0 | 57.7 | 47.5 | 33.7 | 18.8 | ||||||||||
| Property, Plant & Equipment | CZK mil | 37.0 | 50.5 | 38.6 | 20.3 | 11.6 | ||||||||||
| Intangible Assets | CZK mil | 3.56 | 6.73 | 8.41 | 12.9 | 6.78 | ||||||||||
| Current Assets | CZK mil | 3,084 | 2,321 | 2,295 | 1,959 | 2,066 | ||||||||||
| Inventories | CZK mil | 1,677 | 1,163 | 1,250 | 813 | 667 | ||||||||||
| Receivables | CZK mil | 1,114 | 1,025 | 918 | 659 | 663 | ||||||||||
| Cash & Cash Equivalents | CZK mil | 226 | 0.438 | 0.680 | 0.193 | 515 | ||||||||||
| Total Assets | CZK mil | 3,166 | 2,418 | 2,374 | 2,019 | 2,107 | ||||||||||
| Shareholders' Equity | CZK mil | 1,363 | 1,369 | 1,340 | 1,301 | 1,338 | ||||||||||
| Of Which Minority Interest | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Liabilities | CZK mil | 1,802 | 1,050 | 1,034 | 718 | 768 | ||||||||||
| Non-Current Liabilities | CZK mil | 55.0 | 59.5 | 91.3 | 61.5 | 55.7 | ||||||||||
| Long-Term Debt | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Deferred Tax Liabilities | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Current Liabilities | CZK mil | 1,747 | 990 | 943 | 656 | 713 | ||||||||||
| Short-Term Debt | CZK mil | 362 | 240 | 320 | 0 | 0 | ||||||||||
| Trade Payables | CZK mil | 1,094 | 445 | 332 | 289 | 347 | ||||||||||
| Provisions | CZK mil | 55.0 | 57.3 | 85.1 | 56.3 | 51.5 | ||||||||||
| Equity And Liabilities | CZK mil | 3,166 | 2,418 | 2,374 | 2,019 | 2,107 | ||||||||||
| growth rates | ||||||||||||||||
| Total Asset Growth | % | ... | 15.9 | -23.6 | -1.81 | -15.0 | 4.34 | |||||||||
| Shareholders' Equity Growth | % | ... | 21.4 | 0.377 | -2.06 | -2.90 | 2.83 | |||||||||
| Net Debt Growth | % | ... | -18.8 | 76.2 | 33.3 | -100 | 266,920 | |||||||||
| Total Debt Growth | % | ... | 74.0 | -33.7 | 33.3 | -100 | ... | ... | ... | |||||||
| ratios | ||||||||||||||||
| Total Debt | CZK mil | 362 | 240 | 320 | 0 | 0 | ||||||||||
| Net Debt | CZK mil | 136 | 240 | 319 | -0.193 | -515 | ||||||||||
| Working Capital | CZK mil | 1,697 | 1,744 | 1,837 | 1,184 | 983 | ||||||||||
| Capital Employed | CZK mil | 1,739 | 1,801 | 1,884 | 1,218 | 1,002 | ||||||||||
| Net Debt/Equity | % | 9.97 | 17.5 | 23.8 | -0.015 | -38.5 | ||||||||||
| Cost of Financing | % | ... | 1.64 | 1.09 | 1.94 | 1.42 | ... | ... | ... |
| cash flow | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| cash flow | ||||||||||||||||
| Net Profit | CZK mil | 240 | 164 | 127 | 87.7 | 125 | ||||||||||
| Depreciation | CZK mil | 19.3 | 18.3 | 19.9 | 20.2 | 11.6 | ||||||||||
| Non-Cash Items | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||||||
| Change in Working Capital | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Capital Expenditures | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Other Investments | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Dividends Paid | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||
| Issuance Of Shares | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||
| Issuance Of Debt | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| ratios | ||||||||||||||||
| Days Sales Outstanding | days | 69.8 | 65.3 | 59.3 | 49.6 | 55.2 | ||||||||||
| Days Sales Of Inventory | days | 118 | 84.4 | 91.3 | 69.7 | 62.7 | ||||||||||
| Days Payable Outstanding | days | 76.7 | 32.3 | 24.2 | 24.7 | 32.6 | ||||||||||
| Cash Conversion Cycle | days | 111 | 117 | 126 | 94.5 | 85.4 | ||||||||||
| Cash Earnings | CZK mil | 259 | 182 | 147 | 108 | 136 | ||||||||||
| Free Cash Flow | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... |
| other data | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| other data | ||||||||||||||||
| ROA | % | 8.14 | 5.87 | 5.32 | 3.99 | 6.04 | ||||||||||
| Gross Margin | % | 10.7 | 12.4 | 11.5 | 12.3 | 11.4 | ||||||||||
| Employees | 264 | 262 | 239 | 246 | 183 | |||||||||||
| Cost Per Employee | USD per month | 5,062 | 5,117 | 5,978 | 5,537 | 5,678 | ||||||||||
| Cost Per Employee (Local Currency) | CZK per month | 89,532 | 100,080 | 116,960 | 118,335 | 135,534 | ||||||||||
| Staff Cost (As % Of Total Cost) | % | 5.12 | 5.70 | 6.12 | 7.38 | 7.00 | ||||||||||
| Effective Tax Rate | % | 16.2 | 22.9 | 21.9 | 25.0 | 16.4 | ||||||||||
| Capital Expenditures (As % of Sales) | % | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Revenues From Abroad | CZK mil | 2,325 | 2,423 | 2,348 | 1,780 | 1,501 | ||||||||||
| Revenues From Abroad (As % Of Total) | % | 39.9 | 42.2 | 41.5 | 36.7 | 34.3 | ||||||||||
| Domestic Sales of Services | CZK mil | ... | ... | 0.588 | 0 | 0 | 0 | 3.09 | ||||||||
| Export of Services | CZK mil | 1,960 | 2,042 | 2,026 | 1,529 | 1,281 | ||||||||||
| Domestic Sales of Goods | CZK mil | 3,503 | 3,313 | 3,305 | 3,075 | 2,874 | ||||||||||
| Export of Goods | CZK mil | 365 | 380 | 322 | 252 | 220 |
Get all company financials in excel:
GlaxoSmithKline, s.r.o. is a Czech Republic-based subsidiary of the British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London. As of March 2014, it was the world's sixth-largest pharmaceutical Company by revenues. The Company was established in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham plc. GSK manufactures drugs and vaccines for major disease areas such as asthma, cancer, infections, diabetes, digestive and mental health conditions, the biggest selling of which were Advair, Avodart, Flovent, Augmentin, Lovaza, and Lamictal.
GlaxoSmithKline Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has fallen on average by 16.1% a year during that time to total of CZK 97.4 mil in 2017, or 3.36% of sales. That’s compared to 2.92% average margin seen in last five years.
The company netted CZK 65.4 mil in 2017 implying ROE of 4.30% and ROCE of 5.87%. Again, the average figures were 6.49% and 6.67%, respectively when looking at the previous 5 years.
GlaxoSmithKline Czech Republic’s net debt amounted to CZK -209 mil at the end of 2017, or -13.8% of equity. When compared to EBITDA, net debt was -2.15x, down when compared to average of -1.95x seen in the last 5 years.
Helgi Library 
